Match tier Listed
Presence Current · Arkansas
Last published 2021
Sources OpenAlex · ORCID
Refreshed 2026-10-06

Anna Radomińska‐Pandya

High Impact

Role not yet determined Is this you? Add your title

Also affiliated: Boston University (2001); Tufts University (2008–2011); Centre National de la Recherche Scientifique (1999); Arkansas Children's Hospital (2011–2012); Salk Institute for Biological Studies (2001–2003); University of Helsinki (2006–2014); Howard Hughes Medical Institute (2001–2003); Eastern Virginia Medical School (2006); Gdańsk University of Technology (2012); University of Pittsburgh (2003); Washington University in St. Louis (2009); University of Michigan (2012); University of Arkansas Medical Center (2008–2021); University of Alabama at Birmingham (2000); University of California San Diego (2003); Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (1999); Cayman Chemical (United States) (2012); Michigan Medicine (2012); Arkansas State Crime Laboratory (2011–2012); Arkansas Department of Health (2009–2012); Institut National de la Recherche Agronomique (1999); Université Paul Verlaine - Metz (2006); Université Henri Poincaré (1999)

41 h-index 123 pubs 6,149 cited

  • Humans
  • Glucuronosyltransferase
  • Animals
  • Recombinant Proteins
  • Kinetics
  • Microsomes, Liver
  • Male
  • Glucuronides
  • Indoles
  • Liver
  • Female
  • Binding Sites
  • Isoenzymes
  • Naphthalenes
  • Substrate Specificity

Biography and Research Information

OverviewAI-generated summary

Anna Radomińska‐Pandya's research focuses on the metabolic pathways of drugs and xenobiotics, particularly the role of UDP-glucuronosyltransferases (UGTs) and nuclear receptors in detoxification processes. Her work has investigated the structural and functional aspects of UGT enzymes, including the crystal structure of the cofactor-binding domain of human UGT2B7. She has also explored the involvement of nuclear receptors like SXR/PXR and CAR in the metabolism of various compounds, such as cholestatic bile acids and carcinogens.

More recently, her research has extended to the metabolism and toxicity of synthetic cannabinoids found in products like K2/Spice. This work includes characterizing the cytochrome P450-mediated oxidative metabolism of these compounds and identifying novel cannabinoid receptor ligands. Radomińska‐Pandya has also examined human PXR variants and their differential effects on UGT gene expression, contributing to the understanding of inter-individual variability in drug metabolism.

Her scholarly contributions are reflected in a high-impact research profile, evidenced by an h-index of 41, over 119 total publications, and more than 6,100 citations. She has collaborated with researchers at the University of Arkansas for Medical Sciences, including Alicja Urbaniak, Paul L. Prather, Amal Shoeib, and Azure L. Yarbrough.

Metrics

  • h-index: 41
  • Publications: 123
  • Citations: 6,149

Selected Publications

  • Characterization of cannabinoid receptors expressed in Ewing sarcoma TC-71 and A-673 cells as potential targets for anti-cancer drug development (2021)
    Life Sciences 5 citations DOI OpenAlex
  • Natural and Synthetic Cannabinoids Reduce Cell Viability of Ewing Sarcoma TC‐71 Cells Potentially via Non‐canonical CB receptors (2021)
    The FASEB Journal DOI OpenAlex
  • Significance of Competing Metabolic Pathways for 5F-APINACA Based on Quantitative Kinetics (2020)
    Molecules 3 citations DOI OpenAlex
  • Metabolism, CB1 cannabinoid receptor binding and in vivo activity of synthetic cannabinoid 5F-AKB48: Implications for toxicity (2020)
    Pharmacology Biochemistry and Behavior 17 citations DOI OpenAlex
  • Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N‐(adamantan‐1‐yl)‐1‐(5‐fluoropentyl)‐1H‐indole‐3‐carboxamide (STS‐135) (2020)
    Pharmacology Research & Perspectives 9 citations DOI OpenAlex
  • Oxidative Metabolism and Comparative Analysis of Synthetic Cannabinoid N‐(1‐adamantyl)‐1‐(5‐fluoropentyl)indazole‐3‐carboxamide (5F‐AKB‐48) and the Unfluorinated Analog AKB‐48 (2019)
    The FASEB Journal 1 citation DOI OpenAlex
  • Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22) (2019)
    Xenobiotica 4 citations DOI OpenAlex
  • Oxidative metabolism of synthetic cannabinoid STS-135 by recombinant P450S and human liver microsomes (2019)
    Drug Metabolism and Pharmacokinetics DOI OpenAlex
  • Natural compounds activating cannabinoid receptors CB1 and CB2: future for cancer treatments (2018)
    Acta Biochimica Polonica OpenAlex
  • Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice (2018)
    Journal of Pharmacology and Experimental Therapeutics 25 citations DOI OpenAlex
  • Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ9-THC (2018)
    Frontiers in Pharmacology 21 citations DOI OpenAlex
  • Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants (2018)
    Biochemical and Biophysical Research Communications 29 citations DOI OpenAlex
  • Biological Activity of Resveratrol‐Hydroxycinnamic Acid Ester Conjugates (2017)
    The FASEB Journal 3 citations DOI OpenAlex
  • Identification of Novel Variants of the CB 1 Cannabinoid Receptor in Cancer Cells (2017)
    The FASEB Journal DOI OpenAlex
  • Synthetic Cannabinoids: Rapidly Emerging Drugs of Abuse (2017)
    The FASEB Journal 1 citation DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

224 Collaborators 61 Institutions 10 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics